Market Overview

SunTrust Sees Further Pfizer Inc. Bid For AstraZeneca PLC (ADR) 'Highly Likely'

Related AZN
ISIS-STAT3 Rx And ISIS-AR Rx Data Presented By AstraZeneca At European Cancer Symposium
Bank Of America Believes DAPT Adds To Precedent For PEGASUS Success For AstraZeneca
Divided Government Won't Halt Street's Run (Fox Business)
Related PFE
When There's A Pullback On A Bull, Look At These Leading ETFs
U.S. Markets Recover From Early-Day Losses As Japan's Economy Contracts
Divided Government Won't Halt Street's Run (Fox Business)

Pfizer Inc. (NYSE: PFE) is likely to boost its offer for British drug maker AstraZeneca PLC (ADR) (NYSE: AZN) to $96.28 a share, an analyst said Tuesday.

SunTrust's John Boris said a deal would cut Pfizer's tax rate to 20 percent and said potential Treasury inversion action blocking such action is merely “election year rhetoric.”

The $127 billion offer envisioned by Boris would tack on 6.3 percent to its earlier bid of $120 billion, which AstraZeneca (NYSE: AZN) rejected back in mid-May

AstraZeneca's American Depositary Receipts were recently down two percent at $74.62 from Friday's high, but were still up nearly 26 percent for the year.

Under British rules, AstraZeneca can, starting Tuesday, invite it back for talks or Pfizer can make a single "knock-out" bid which it believes would be accepted. Pfizer (NYSE: PFE) can also start a more conventional bidding process over again, beginning in November.

Posted-In: John Boris SunTrustAnalyst Color News Rumors M&A

 

Related Articles (AZN + PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters